Pharvaris Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-demand Treatment of HAE at the GA²LEN UCARE Conference 2023

December 10, 2023

https://www.globenewswire.com/news-release/2023/12/08/2793405/0/en/Pharvaris-Presents-Deucrictibant-Clinical-Data-and-Analysis-of-Endpoints-for-Trials-of-On-demand-Treatment-of-HAE-at-the-GA-LEN-UCARE-Conference-2023.html

ZUG, Switzerland, Dec. 08, 2023 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq:PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the presentation of one oral session and two posters at the Global Allergy and Asthma Excellence Network (GA²LEN) Urticaria Centers of Reference and Excellence (UCARE) Conference, being held from December 7-9, 2023, at the Rebouças Convention Center in São Paulo, Brazil.

Read more at globenewswire.com

Related news for (PHVS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.